BR0311247A - Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2 - Google Patents
Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2Info
- Publication number
- BR0311247A BR0311247A BR0311247-0A BR0311247A BR0311247A BR 0311247 A BR0311247 A BR 0311247A BR 0311247 A BR0311247 A BR 0311247A BR 0311247 A BR0311247 A BR 0311247A
- Authority
- BR
- Brazil
- Prior art keywords
- prostaglandin
- group
- receptor antagonist
- hydrogen atom
- antagonist peptide
- Prior art date
Links
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 title abstract 3
- 229960002986 dinoprostone Drugs 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 101150109738 Ptger4 gene Proteins 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 210000001100 crypt cell Anatomy 0.000 abstract 1
- 210000003017 ductus arteriosus Anatomy 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38233602P | 2002-05-23 | 2002-05-23 | |
| PCT/CA2003/000771 WO2003099857A1 (en) | 2002-05-23 | 2003-05-23 | Antagonistic peptides of prostaglandin e2 receptor subtype ep4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0311247A true BR0311247A (pt) | 2005-03-15 |
Family
ID=29584392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0311247-0A BR0311247A (pt) | 2002-05-23 | 2003-05-23 | Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040023853A1 (https=) |
| EP (1) | EP1506220A1 (https=) |
| JP (1) | JP2006506327A (https=) |
| CN (1) | CN1662551A (https=) |
| AU (1) | AU2003233297A1 (https=) |
| BR (1) | BR0311247A (https=) |
| CA (1) | CA2485485A1 (https=) |
| WO (1) | WO2003099857A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1742662A2 (en) * | 2004-05-03 | 2007-01-17 | Astellas Pharma Inc. | Combination of prostaglandin e2 receptor antagonists and renin-angiotensin system inhibitors for treating renal diseases |
| US20060115785A1 (en) | 2004-11-30 | 2006-06-01 | Chunhua Li | Systems and methods for intra-oral drug delivery |
| WO2007146187A2 (en) * | 2006-06-06 | 2007-12-21 | Reika Ortho Technologies, Inc. | Transduction orthodontic devices |
| CN101041687B (zh) * | 2007-02-28 | 2010-09-29 | 长春博泰医药生物技术有限责任公司 | Pge2特异结合的噬菌体环七肽及筛选方法和合成肽的用途 |
| JPWO2010087425A1 (ja) | 2009-01-30 | 2012-08-02 | 国立大学法人京都大学 | 前立腺癌の進行抑制剤および進行抑制方法 |
| JP5273689B2 (ja) | 2010-09-29 | 2013-08-28 | 株式会社エヌビィー健康研究所 | ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体 |
| HRP20180703T1 (hr) | 2013-06-12 | 2018-06-15 | Kaken Pharmaceutical Co., Ltd. | Derivat 4-alkinil imidazola i lijek koji kao aktivni sastojak sadrži isti |
| TW201623277A (zh) * | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| WO2016196400A1 (en) | 2015-05-29 | 2016-12-08 | Purdue Research Foundation | Bone fracture repair by targeting of agents that promote bone healing |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| CN110621671A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物 |
| EP3625224B1 (en) | 2017-05-18 | 2021-08-04 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| PL3625228T3 (pl) | 2017-05-18 | 2021-12-20 | Idorsia Pharmaceuticals Ltd | Pochodne pirymidyny jako modulatory receptora pge2 |
| CN110621667A (zh) | 2017-05-18 | 2019-12-27 | 爱杜西亚药品有限公司 | 嘧啶衍生物 |
| EA201992676A1 (ru) | 2017-05-18 | 2020-05-06 | Идорсия Фармасьютиклз Лтд | Фенильные производные в качестве модуляторов pge2 рецепторов |
| US20230390303A1 (en) | 2020-11-13 | 2023-12-07 | Ono Pharmaceutical Co., Ltd. | Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor |
| EP4603087A1 (en) * | 2022-11-21 | 2025-08-20 | Kyowa Hakko Bio Co., Ltd. | Prophylactic or therapeutic agent for acute kidney injury induced by anticancer agent |
| WO2025115623A1 (ja) * | 2023-11-28 | 2025-06-05 | 新田ゼラチン株式会社 | プロスタグランジンｅ２産生抑制剤、それを含む飲食品、プロスタグランジンｅ２産生抑制方法、およびプロスタグランジンｅ２産生抑制剤の製造方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605814A (en) * | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
| TWI247606B (en) * | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
| ATE298346T1 (de) * | 1999-12-06 | 2005-07-15 | Chu Sainte Justine | Verbindungen zur behandlung von abnormaler glomerularer filtration, patent ductus arteriosus und osteoporosis |
-
2003
- 2003-05-23 JP JP2004508111A patent/JP2006506327A/ja active Pending
- 2003-05-23 WO PCT/CA2003/000771 patent/WO2003099857A1/en not_active Ceased
- 2003-05-23 CA CA002485485A patent/CA2485485A1/en not_active Abandoned
- 2003-05-23 CN CN038146851A patent/CN1662551A/zh active Pending
- 2003-05-23 BR BR0311247-0A patent/BR0311247A/pt not_active IP Right Cessation
- 2003-05-23 US US10/444,516 patent/US20040023853A1/en not_active Abandoned
- 2003-05-23 AU AU2003233297A patent/AU2003233297A1/en not_active Abandoned
- 2003-05-23 EP EP03727063A patent/EP1506220A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003099857A1 (en) | 2003-12-04 |
| EP1506220A1 (en) | 2005-02-16 |
| AU2003233297A1 (en) | 2003-12-12 |
| US20040023853A1 (en) | 2004-02-05 |
| WO2003099857B1 (en) | 2004-02-19 |
| CN1662551A (zh) | 2005-08-31 |
| AU2003233297A2 (en) | 2003-12-12 |
| CA2485485A1 (en) | 2003-12-04 |
| JP2006506327A (ja) | 2006-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0311247A (pt) | Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2 | |
| DE60119968T2 (de) | Hepatitis c tripeptid inhibitoren | |
| SK2052001A3 (en) | Peptide analogues, process for their preparation, pharmaceutical composition containing same, their use and intermediates | |
| CA2660183C (en) | Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer | |
| Takagi et al. | Discovery of novel cyclic peptide inhibitors of dengue virus NS2B-NS3 protease with antiviral activity | |
| DE60324552D1 (en) | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren | |
| IS7533A (is) | Lifrarbólgu C-veirutálmar | |
| CN1125400A (zh) | 九肽和十肽在治疗爱滋病药物的制备中的应用 | |
| BRPI0516825A (pt) | inibição da protease ns3-ns4a do vìrus da hepatite c (vhc) | |
| ATE481106T1 (de) | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer | |
| BR0013248A (pt) | Inibidores da adesão celular | |
| ATE442378T1 (de) | Substituierte wt1-peptide | |
| PT95581A (pt) | Processo para a preparacao de compostos peptidicos antagonistas do receptor do fibrinogenio | |
| Jin et al. | Synthesis and antibacterial studies of teixobactin analogues with non-isostere substitution of enduracididine | |
| BR9808017A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratar o câncer em um mamìfero e para a fabricação de um medicamento para o tratamento do câncer | |
| AU638468B2 (en) | Hemoregulatory peptides | |
| CY1107990T1 (el) | Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων | |
| Monaim et al. | Solid-phase synthesis of homodetic cyclic peptides from Fmoc-MeDbz-resin | |
| MY147920A (en) | Antibacterial and antiviral peptides from actinomadura namibiensis | |
| EA200400603A1 (ru) | Новые пептиды - аналоги гормона высвобождения гормона роста человека | |
| CN114096265B (zh) | 衰老进程抑制剂 | |
| EP1878741A3 (en) | Antagonistic peptides of prostaglandin E2 receptor subtype EP4 | |
| Wleklik et al. | Tuftsin, a natural peptide with antiviral activity-structural basis of its action | |
| Stefanowicz et al. | Threonine at position 6 is not essential for the immunosuppressive activity of HLA-DQ (β164–172)-hexapeptide | |
| JP2005126360A (ja) | 新規なポリペプチドで構成されたコラゲナーゼ阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010. |